Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences is launching a restructuring plan to cut operating costs and support its path to breakeven without additional equity capital. The company will reduce headcount by 43 employees, about 20% of its global workforce, trim research and development spending, limit marketing, travel and administrative costs, and leave some open roles unfilled. It expects a cash restructuring charge of approximately $2.7 million to $3.0 million and a non-cash reduction in stock-based compensation of about $0.6 million to $1.0 million, primarily in the third quarter of 2025. The workforce plan alone is estimated to yield around $11.9 million in annualized savings. The company also announced that its Chief Commercial Officer, Matthew Link, will step down effective August 31, 2025, with his severance included in the restructuring costs. Sight Sciences reaffirmed its 2025 revenue guidance of $72.0 million to $76.0 million, reiterated that third quarter 2025 surgical glaucoma revenue is expected to be down by mid-single digits year over year, and lowered its 2025 adjusted operating expense guidance to $95 million to $99 million from $101 million to $105 million.
Sight Sciences, Inc. (SGHT) – Form 4 insider transaction
Chief Technology Officer & Director David Badawi disclosed the sale of 5,679 common shares on 03 July 2025 at an average price of $4.174 per share. The disposition was executed to satisfy statutory tax-withholding obligations generated by the vesting of restricted stock units, as noted in the filing’s footnote.
Following the sale, Badawi’s direct beneficial ownership stands at 1,831,025 shares. No derivative securities were reported, and there were no purchases.
The Form 4 indicates an automatic, non-discretionary sale (code “S”) under Rule 16a to cover taxes, which generally carries less negative signaling than voluntary open-market sales. The transaction represents approximately 0.3 % of Badawi’s post-transaction holdings and an immaterial percentage of SGHT’s total shares outstanding.
On 07/02/2025, Sight Sciences (SGHT) Chief Commercial Officer Matthew Link filed a Form 4 reporting the sale of 4,889 common shares at an average price of $4.098 per share.
The filing notes the shares were sold solely to satisfy the executive’s tax liability related to the vesting of restricted stock units. Following the transaction, Link continues to hold 832,293 shares of SGHT, retaining more than 99% of his previous direct ownership. No derivative securities were acquired or disposed of.
The sale represents a routine, low-volume insider disposition—approximately 0.6% of the executive’s holdings—and is unlikely to materially affect investor sentiment or the company’s share-price outlook.